Please ensure Javascript is enabled for purposes of website accessibility

Why MacroGenics Stock Jumped Today

By Keith Speights - Updated Jan 25, 2021 at 3:41PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company published data from a late-stage study of its promising breast cancer drug.

What happened

Shares of MacroGenics (MGNX 2.05%) had jumped 5.3% as of 3:09 p.m. EST on Monday. The gain came after the company announced results from a late-stage study of Margenza as a third-line treatment for metastatic HER2-positive breast cancer. These results were published in the Journal of the American Medical Association Oncology

So what

MacroGenics stated that Margenza met the primary endpoint of the phase 3 study with a 24% progression-free survival relative risk reduction versus Roche's Herceptin. Both Margenza and Herceptin were administered along with chemotherapy.

Physician holding a pink ribbon symbolizing breast cancer awareness

Image source: Getty Images.

Investors reacted positively to the latest results, which bode well for Margenza's prospects in achieving commercial success. The drug won Food and Drug Administration approval as a third-line treatment for HER2-positive breast cancer in December.

CEO Scott Koenig said that Margenza is "the first HER2-targeted therapy to reduce the risk of disease progression in metastatic breast cancer patients over trastuzumab [Herceptin] in a head-to-head comparison involving a heavily pre-treated patient population." The potential market opportunity for Margenza should be significant. As many as 20% of breast cancers diagnosed are HER2-positive. Herceptin has long been a leading treatment for HER2-positive breast cancer. An even better therapy would be welcomed by physicians and patients.

Now what

What's the next likely catalyst for the biotech stock? MacroGenics expects to launch Margenza in the U.S. beginning in March. The company's first-quarter update could provide a hint as to how the rollout is going, but its second-quarter update will likely give a better picture.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

MacroGenics, Inc. Stock Quote
MacroGenics, Inc.
MGNX
$3.98 (2.05%) $0.08
Roche Holding AG Stock Quote
Roche Holding AG
RHHBY
$41.11 (0.91%) $0.37

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
330%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/22/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.